CA Patent

CA3174176A1 — Compounds active towards nuclear receptors

Assigned to Nuevolution AS · Expires 2021-10-07 · 5y expired

What this patent protects

Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.

USPTO Abstract

Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.

Drugs covered by this patent

Patent Metadata

Patent number
CA3174176A1
Jurisdiction
CA
Classification
—
Expires
2021-10-07
Drug substance claim
No
Drug product claim
No
Assignee
Nuevolution AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.